Healthcare Industry News: Cytokine Storm
News Release - April 19, 2006
GenoMed to Offer Free Mumps Trial
ST. LOUIS, April 19 (HSMN NewsFeed) -- GenoMed, Inc. ("the Company" or "GenoMed") (Pink Sheets: GMED ), a St. Louis, Missouri-based Next Generation Disease Management company whose business is public health(TM), announced today that it is offering a free clinical trial for mumps, using already existing medications. (The cost of the drugs, about $1 a day, is extra.)Said David Moskowitz, MD, GenoMed's CEO and Chief Medical Officer, "Unlike West Nile virus, the mumps virus is no more lethal than the common cold, but it causes a lot of discomfort. As with most viruses, disease in humans is caused by a 'Cytokine Storm,' not by the virus itself. Our approach is to calm the 'Cytokine Storm' in the host and ignore the virus. Our goal is to turn the patient into an asymptomatic shedder, which is what happens normally."
Added Dr. Moskowitz, "Our approach should work for most viruses in most people and animals. The more experience we get with different viruses, the more credible this approach becomes, and the readier we'll be for something really big, like avian flu or a viral bioterrorist attack."
GenoMed holds a pending patent for its approach in the U.S. but not the rest of the world. It was included in the Project BioShield Act of 2005 co-sponsored by Senators Lieberman, Hatch, and Brownback (see Section 2151 of Senate bill S.975, available at: http://www.govtrack.us/congress/billtext.xpd?bill=s109-975 ). Introduced a year ago, this bill has not yet been discussed. The White House requested a briefing about GenoMed's possible viral antidote in the summer of 2004, and the Department of Homeland Security and the National Institutes of Health agreed to a briefing in the fall of that year. For the past three years, the World Health Organization has not returned any phone calls or emails on this subject. The Centers for Disease Control complained to the FDA about GenoMed's West Nile virus trial in June, 2004, but the FDA dropped the case as soon as it began investigating it in August, 2005.
To enroll in GenoMed's free clinical trial for mumps, simply contact Dr. Moskowitz.
About GenoMed
GenoMed is a Next Generation DM(tm) company that has found what it believes to be the "master" disease gene. It has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of end-stage emphysema; and begin to see success in treating cancer and autoimmune diseases. GenoMed's near-universal viral antidote is simply another consequence of the "master" disease gene, which alone promises to revolutionize healthcare globally. Despite the usual obstacles facing any biotech start-up company, GenoMed perseveres in its mission to improve public health through genomics, promising a significant return to both patients and shareholders.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," "promises" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to GenoMed's research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
Source: GenoMed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
